By Fineline Cube 
Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ) announced that the first patient has been dosed in China for its self-developed Class 1 innovative drug, TQB6411 for injection (EGFR/c-MET bispecific ADC). This milestone marks the commencement of the Phase I clinical trial.
NMPA Approval and Drug Profile
The National Medical Products Administration (NMPA) approved the drug on June 13 for the treatment of advanced malignant tumors. TQB6411 is recognized as one of the top-tier bispecific ADCs globally, with all similar drugs currently in Phase I development.
Mechanism and Preclinical Results
TQB6411 is a bispecific antibody-drug conjugate (ADC) targeting both EGFR and c-MET. Preclinical studies have demonstrated its anti-tumor activity across various expression and resistant models, with controllable toxicity risks.
Clinical Trial Details
The Phase I clinical trial will assess TQB6411’s safety, tolerability, pharmacokinetic profile, and preliminary efficacy. Sino Biopharmaceutical continues to advance its pipeline, with several other ADC products in clinical development.-Fineline Info & Tech